کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8538327 | 1561109 | 2018 | 12 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
WIN-55,212-2SERMCB2RCB1RGPCRTRAPCP-55,940DMEMIBMXG-protein coupled receptor - G-پروتئین همراه گیرندهG-protein coupled receptors - G-پروتئین گیرنده های متصل شده[35S]GTPγS - [35S] GTPγSadenylyl cyclase - آدنیلات سیکلاز، آدنیلیل سیکلازAntagonist - آنتاگونیستInverse agonist - آگونیست معکوسtartrate-resistant acid phosphatase - اسید فسفاتاز مقاوم در برابر تارتاتDulbecco's modification of Eagle's medium - اصلاح Dulbecco از محیط عقابDrug action - اقدامات داروییCho - برایChinese Hamster Ovary - تخمدان هامستر چینیELISA - تست الیزاEnzyme-linked immunosorbent assay - تست الیزاrid - خلاص شدن از شرSelective estrogen receptor modulator - مدولاتور گیرنده استروژن انتخابیcannabinoid receptor type 1 - نوع گیرنده کانابینوئید 1Estrogen receptor - گیرنده استروژنcannabinoid receptors - گیرنده های کانابینوئیدcannabinoid receptor type 2 - گیرنده کانابینوئید نوع 2
موضوعات مرتبط
علوم زیستی و بیوفناوری
علوم محیط زیست
بهداشت، سم شناسی و جهش زایی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects](/preview/png/8538327.png)
چکیده انگلیسی
Selective estrogen receptor modulators (SERMs) target estrogen receptors (ERs) to treat breast cancer and osteoporosis. Several SERMs exhibit anti-cancer activity not related to ERs. To discover novel anti-cancer drugs acting via ER-independent mechanisms, derivatives of the SERM tamoxifen, known as the “ridaifen” compounds, have been developed that exhibit reduced or no ER affinity, while maintaining cytotoxicity. Tamoxifen and other SERMs bind to cannabinoid receptors with moderate affinity. Therefore, ER-independent effects of SERMs might be mediated via cannabinoid receptors. This study determined whether RID-B, a first generation ridaifen compound, exhibits affinity and/or activity at CB1 and/or CB2 cannabinoid receptors. RID-B binds with high affinity (Kiâ¯=â¯43.7â¯nM) and 17-fold selectivity to CB2 over CB1 receptors. RID-B acts as an inverse agonist at CB2 receptors, modulating G-protein and adenylyl cyclase activity with potency values predicted by CB2 affinity. Characteristic of an antagonist, RID-B co-incubation produces a parallel-rightward shift in the concentration-effect curve of CB2 agonist WIN-55,212-2 to inhibit adenylyl cyclase activity. CB2 inverse agonists are reported to exhibit anti-inflammatory and anti-ostoeclastogenic effects. In LPS-activated macrophages, RID-B exhibits anti-inflammatory effects by reducing levels of nitric oxide (NO), IL-6 and IL-1α, but not TNFα. Only reduction of NO concentration by RID-B is mediated by cannabinoid receptors. RID-B also exhibits pronounced anti-osteoclastogenic effects, reducing the number of osteoclasts differentiating from primary bone marrow macrophages in a cannabinoid receptor-dependent manner. In summary, the tamoxifen derivative RID-B, developed with reduced affinity for ERs, is a high affinity selective CB2 inverse agonist with anti-inflammatory and anti-osteoclastogenic properties.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Toxicology and Applied Pharmacology - Volume 353, 15 August 2018, Pages 31-42
Journal: Toxicology and Applied Pharmacology - Volume 353, 15 August 2018, Pages 31-42
نویسندگان
Lirit N. Franks, Benjamin M. Ford, Toshifumi Fujiwara, Haibo Zhao, Paul L. Prather,